No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 37.6x · 10Y median 13.5x · 97th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 11
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T14:32:03.774Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for GRAIL Inc. (GRAL) stock was $144.83 as of Oct 6, 2026, 10:30 AM EDT, down 6.00% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +134.1%
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer.
Medical - Diagnostics & Research · Menlo Park, CA
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Nov 11, 2026
36 days away
EPS Estimate
-2.50
Revenue Est.
$44.20M
Last Quarter Results
EPS
$-1.34
vs Estimate
$-2.43
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1GRAL | $6.22B | $144.83 | -6.00% | +134.10% | N/A | N/A | N/A |
| 2AMRX | $6.40B | $20.05 | -1.50% | +95.23% | +30.25% | -1.73% | vs GRAL |
| 3LGND | $5.94B | $296.50 | -3.35% | +69.07% | +30.72% | +17.12% | vs GRAL |
| 4HIMS | $6.52B | $29.23 | -1.47% | -43.37% | +32.23% | N/A | vs GRAL |
| 5LNTH | $6.53B | $100.28 | +0.09% | +85.57% | +31.73% | +28.40% | vs GRAL |
| 6IOVA | $5.89B | $13.20 | -6.70% | +499.53% | -11.55% | +5.84% | vs GRAL |
N/A
$44.69M
vs Estimate
$42.39M
Consensus Rating
Based on 10 analysts
Average Price Target
$112.40
-22.4% downside
Low
$60.00
Current
$144.83
High
$175.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-2.65 | $-2.50 | $-2.25 | 3 |
| Quarter ending Dec 2026 | $-2.97 | $-2.50 | $-2.26 | 4 |
| Quarter ending Mar 2027 | $-2.83 | $-2.69 | $-2.55 | 1 |
| Quarter ending Jun 2027 | $-2.78 | $-2.64 | $-2.51 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-10.27 | $-9.62 | $-9.04 | 5 |
| FY 2027 | $-10.56 | $-10.20 | $-9.78 | 5 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $43.77M | $44.20M | $44.62M | 6 |
| Quarter ending Dec 2026 | $50.01M | $51.16M | $52.30M | 6 |
| Quarter ending Mar 2027 | $46.85M | $48.76M | $50.66M | 3 |
| Quarter ending Jun 2027 | $53.27M | $55.44M | $57.61M | 3 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $177.81M | $180.80M | $183.66M | 8 |
| FY 2027 | $214.16M | $226.62M | $245.54M | 8 |
